Physician profile
William H Snyder
NPI 1730131012
$2,720.28
in general payments reported to CMS, 2019-2025
36 companies · $532 in 2025
The $532 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $927 · 2020: $141 · 2021: $80.28 · 2022: $109 · 2023: $442 · 2024: $489 · 2025: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $457.69 | 2019-2025 | |
| Glaxosmithkline, LLC. | $262.14 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $213.64 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $191.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $186.78 | 2019-2025 | Repatha, Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $139.10 | 2019-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.73 | 2019-2025 | Jardiance |
| Abbott Laboratories | $97.34 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.97 | 2019-2025 | Xifaxan |
| Abbvie INC. | $80.65 | 2023-2024 | Ubrelvy, Qulipta, Vraylar |
| Janssen Pharmaceuticals, INC | $79.41 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $76.13 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $63.22 | 2023-2025 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $52.40 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $51.88 | 2019 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.